koolferro.blogg.se - What is the new serial podcast about

#What is the new serial podcast about trial#
#What is the new serial podcast about series#

November 4: Discovery at the DNA Encoded LibraryĪlex Gouliaev, Ph.D., vice president, Amgen Research CopenhagenĬarolyn Bertozzi, Ph.D., professor of Chemistry, Stanford Ryan Potts, Ph.D., executive director, Research and head of Induced Proximity Platform at AmgenĬraig Crews, Ph.D., professor of Molecular, Cellular and Developmental Biology, Yale October 21: The Next Wave of Drug Development

#What is the new serial podcast about series#

You can find Undruggable here or by subscribing to The Scientist's series LabTalk on Apple Podcasts, Spotify, Stitcher, Google Podcasts, or wherever you like to listen. The first episode launches today, and the series continues with a new episode every Thursday through November 18.

Joining Deshaies are leaders from Amgen and premier research institutions discussing topics ranging from the promise of induced proximity platforms to the way DNA encoded libraries help scientists screen billions of molecules to find compounds that interact with tricky targets. "I'm thrilled to share these conversations that delve deeper into the ways scientists are designing medicines that go beyond what conventional drugs can accomplish." Once thought to be an insurmountable task, scientists are successfully tackling the problem of undruggable disease targets," said Ray Deshaies, senior vice president of Global Research at Amgen. "We are in an exciting time for drug discovery and development. Undruggable discusses some of the latest advancements enabling scientists to make progress against these challenging diseases. While breakthrough discoveries have been made, 85% of disease targets are still considered undruggable, which represents an ongoing barrier to developing medicines for complex diseases like cancer and autoimmune conditions. Produced in partnership with The Scientist, Undruggable explores the latest wave of innovation, featuring conversations about the new types of multispecific medicines that have the potential to radically alter our concept of how drugs can work and pave the way for new therapies.

Amgen's Commitment to Diversity, Inclusion and Belongingīeginning October 21, Amgen's R&D podcast returns with the new series, Undruggable.

Non-Healthcare Donations and Sponsorships.

Amgen Patient Advocacy and Strategic Alliances.

Access to Medicines Initiatives Outside the U.S.

Reimbursement Support Services and Financial Assistance Programs

Transformative Treatments, Approaches and Technology.

Access Approaches, Treatments, and Collaborations.

Our Approach to Pricing, Access and Affordability.

Environment, Social and Governance Strategy.

Environmental, Social & Governance Report 2020.

Non-Healthcare Donations and SponsorshipsĪmgen's Commitment to Diversity, Inclusion and Belonging Reimbursement Support Services and Financial Assistance ProgramsĪccess to Medicines Initiatives Outside the U.S.Īmgen Patient Advocacy and Strategic Alliances Transformative Treatments, Approaches, and Technology Our Approach to Pricing, Access and AffordabilityĪccess Approaches, Treatments, and Collaborations

#What is the new serial podcast about trial#

Clinical Trial Diversity and RepresentationĬlinical Trial Transparency, Data Sharing and Disclosure PracticesĪdverse Event and Product Complaint ReportingĮnvironmental, Social & Governance Report 2020Įnvironment, Social and Governance Strategy